Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 10, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transfer of 4,168 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991 on November 9, 2004. The company was advised of these transactions on November 10, 2004.
Outlook, Risks, and Management Commentary
The filing contains no guidance, outlook, management commentary, risks, contingencies, or unusual items. It strictly details the mechanics of the share transfer and notes that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe) are interested in the shares held in the GSK Trust in the same capacity as other employees.
Key Facts for Investor Verification
- 4,168 Ordinary Shares were transferred from the GSK Trust to employee plan participants.
- The transaction occurred on November 9, 2004, with notification received on November 10, 2004.
- Three directors hold interests in the GSK Trust as potential beneficiaries alongside other employees.
- No financial performance metrics are included in this specific filing.